Biomaterial Database

Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. 2019

Christine Sekaggya-Wiltshire, and Kelly E Dooley

a Infectious Diseases Institute, Makerere University College of Health Sciences , Kampala , Uganda.

UI	MeSH Term	Description	Entries
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347	Drug Interactions	The action of a drug that may affect the activity, metabolism, or toxicity of another drug.	Drug Interaction,Interaction, Drug,Interactions, Drug
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000904	Antibiotics, Antitubercular	Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.	Antitubercular Antibiotics
D012294	Rifamycins	A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei.	Rifamycin,Rifomycin,Rifomycins
D014376	Tuberculosis	Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses

Related Publications

Christine Sekaggya-Wiltshire, and Kelly E Dooley

Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.

February 1988, Clinical pharmacokinetics,

Christine Sekaggya-Wiltshire, and Kelly E Dooley

Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.

November 2016, Expert opinion on drug metabolism & toxicology,

Christine Sekaggya-Wiltshire, and Kelly E Dooley

Pharmacokinetic and pharmacodynamic considerations of antibiotics and antifungals in liver transplantation recipients.

January 2023, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,

Christine Sekaggya-Wiltshire, and Kelly E Dooley

Pharmacokinetic and pharmacodynamic considerations in the treatment of severe infections.

February 2013, Current clinical pharmacology,

Christine Sekaggya-Wiltshire, and Kelly E Dooley

Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

October 2013, Clinical pharmacokinetics,

Christine Sekaggya-Wiltshire, and Kelly E Dooley

Pharmacokinetic and pharmacodynamic considerations for chronic hemodialysis.

January 1975, Kidney international. Supplement,

Christine Sekaggya-Wiltshire, and Kelly E Dooley

Pharmacokinetic and metabolic studies with labeled rifamycin antibiotics.

January 1966, Antimicrobial agents and chemotherapy,